University of Michigan researchers find compound to target harmful gut bacteria

Scientists have identified a naturally occurring compound that kills the harmful bacterium Clostridioides difficile while leaving the beneficial microbes in the gut untouched, and early laboratory tests show it could become a gentler, more effective therapy for stubborn intestinal infections that often return. The discovery, reported by researchers at the University of Michigan, follows a series of experiments in which the molecule eliminated C. difficile cultures without reducing the diversity of a simulated gut microbiome.

C. difficile infection is a growing public‑health problem, causing about 500,000 cases and up to 29,000 deaths in the United States each year. The disease typically follows a course of broad‑spectrum antibiotics that disrupt the normal gut flora, creating an environment where C. difficile can thrive. Current treatments such as oral vancomycin or fidaxomicin are effective at clearing the pathogen but often leave patients vulnerable to recurrence, with up to 30 % experiencing a second episode within a month. The new compound, a bacteriocin‑like peptide produced by a harmless gut commensal, appears to target a unique protein on the surface of C. difficile, sparing other bacteria and preserving the microbiome’s protective functions.

In the study, the researchers exposed mouse models of infection to the compound and observed a 95 % reduction in C. difficile counts within 48 hours, while 16S rRNA sequencing showed no significant loss of microbial diversity. “We’ve been looking for a way to disarm C. difficile without collateral damage,” said Dr. Emily Carter, the study’s senior author. “This molecule does exactly that, offering a proof of concept for precision antimicrobial therapy.” Independent experts praised the work, noting that a targeted approach could reduce the need for fecal microbiota transplants and lower the risk of antibiotic resistance.

The team plans to move the compound into safety testing and larger animal trials later this year, with the goal of initiating Phase I human studies within two years. If successful, the treatment could reshape how clinicians manage C. difficile, shifting from broad‑spectrum antibiotics to microbiome‑preserving agents. Such a shift would not only improve patient outcomes but also support broader efforts to curb the rise of drug‑resistant infections.